Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
Evolus reported Q2 2026 revenue of $84.1 million, up 21% year-over-year, driven by double-digit growth for Jeuveau and accelerating adoption of Evolysse. The company achieved its third consecutive quarter of positive Adjusted EBITDA at $4.7 million, a $12.6 million improvement from the prior year, and raised its full-year 2026 revenue guidance to $330M-$337M. Strategically, Evolus expanded its global injectable portfolio through exclusive partnerships for Profhilo in the U.S.
Key figures
- Revenue
- $84.1 million
- Guidance
- FY26 revenue $330M-$337M (raised), Adj. EBITDA margin low- to mid-single digits; 2028 revenue $450M-$500M
- Revenue Yoy
- 21%
- Adjusted ebitda
- $4.7 million
- Gross profit margin
- 68.0%
- Cash and equivalents
- $45.2 million
- Adjusted gross profit margin
- 69.0%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.